David L Porter
Overview
Explore the profile of David L Porter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
185
Citations
20219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Gimotty P, Matthews A, Mamtani R, Luger S, Hexner E, et al.
Blood Adv
. 2025 Jan;
9(3):533-544.
PMID: 39888631
Little is known about the impact of recent advances in acute myeloid leukemia (AML) treatment on racial/ethnic disparities in survival outcomes. We performed a retrospective cohort study of patients with...
2.
Maillie L, Nasta S, Svoboda J, Barta S, Chong E, Garfall A, et al.
Transplant Cell Ther
. 2025 Jan;
PMID: 39848443
While immune effector cell-associated neurotoxicity syndrome (ICANS) is a well-defined adverse effect associated with chimeric antigen receptor-modified T cell (CAR-T) therapy, some patients develop prolonged neurologic symptoms. Few studies have...
3.
Jadlowsky J, Hexner E, Marshall A, Grupp S, Frey N, Riley J, et al.
Nat Med
. 2025 Jan;
PMID: 39833408
Long-term risks of gene therapy are not fully understood. In this study, we evaluated safety outcomes in 783 patients over more than 2,200 total patient-years of observation from 38 T...
4.
Riedell P, Grady C, Nastoupil L, Luna A, Luna de Abia A, Ahmed N, et al.
Blood Adv
. 2024 Dec;
9(5):1232-1241.
PMID: 39657136
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor T-cell therapy approved for the treatment of relapsed/refractory large B-cell lymphoma. We present a multicenter retrospective study evaluating safety, efficacy,...
5.
Inconsistent Reporting and Definitions of Time-to-Event Endpoints in CAR T Clinical Trials: A Review
Grady C, Li Y, Maude S, Hexner E, Frey N, Porter D, et al.
Transplant Cell Ther
. 2024 Nov;
PMID: 39603418
Clinical trials evaluating chimeric antigen receptor T-cell therapy (CAR T) commonly report time-to-event (TTE) endpoints. However, definitions are not necessarily comparable across studies and variability can lead to misinterpretation of...
6.
Dimitri A, Baxter A, Chen G, Hopkins C, Rouin G, Huang H, et al.
Sci Adv
. 2024 Nov;
10(46):eadp9371.
PMID: 39536093
CD8 T cell exhaustion hampers control of cancer and chronic infections and limits chimeric antigen receptor (CAR) T cell efficacy. Targeting in CAR T cells provides therapeutic benefit; however, TET2's...
7.
Bhagwat A, Torres L, Shestova O, Shestov M, Mellors P, Fisher H, et al.
Nat Med
. 2024 Sep;
30(12):3697-3708.
PMID: 39333315
Acute myeloid leukemia (AML) is a rapidly progressive malignancy without effective therapies for refractory disease. So far, chimeric antigen receptor (CAR) T cell therapy in AML has not recapitulated the...
8.
Ahmed N, Wesson W, Lutfi F, Porter D, Bachanova V, Nastoupil L, et al.
Blood Adv
. 2024 Jul;
8(20):5346-5354.
PMID: 39042880
CD19-directed chimeric antigen receptor T-cell (CAR T) therapies, including axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel), have transformed the treatment landscape for B-cell non-Hodgkin lymphoma, showcasing significant efficacy...
9.
Ghilardi G, Williamson S, Pajarillo R, Paruzzo L, Chen L, Grady C, et al.
NEJM Evid
. 2024 May;
3(4):EVIDoa2300213.
PMID: 38776868
Background: Administration of anti-CD19 chimeric antigen receptor T-cell (CART19) immunotherapy for large B-cell lymphomas (LBCLs), a subset of non-Hodgkin lymphoma (NHL), involves high costs and access to specialized tertiary care...
10.
Tebas P, Jadlowsky J, Shaw P, Tian L, Esparza E, Brennan A, et al.
J Clin Invest
. 2024 May;
134(9).
PMID: 38690741
No abstract available.